The two companies have announced a collaborative agreement for the development, manufacture, and supply of CT83 (KK-LC-1) mAb.
These will be used to develop a diagnostic test to identify tumors that express KK-LC-1. Patients with KK-LC-1 positive tumors may be eligible inclusion in clinical trial